Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.

Area of Science:

• Neurology
• Clinical Pharmacology

Background:

• Limited treatment options exist for secondary progressive multiple sclerosis (SPMS).
• Open-label studies suggested potential efficacy of mitoxantrone in SPMS.
• This study aimed to validate these findings in a randomized trial.

Purpose of the Study:

• To evaluate the efficacy and safety of mitoxantrone in patients with secondary progressive multiple sclerosis.
• To assess the impact of mitoxantrone on disability progression and clinical exacerbations.

Main Methods:

• A randomized trial involving 194 patients with worsening relapsing-remitting or SPMS.
• Patients received either placebo or mitoxantrone (12 mg/m(2)) intravenously every 3 months for 24 months.
• Clinical assessments were performed every 3 months, with a primary endpoint based on a multivariate analysis of five clinical measures.

Main Results:

• The mitoxantrone group showed significant benefits compared to placebo across primary and secondary efficacy measures.
• Key improvements included reduced disability progression (Expanded Disability Status Scale, ambulation index) and fewer relapses.
• No serious drug-related adverse events or clinically significant cardiac dysfunction were observed.

Conclusions:

• Mitoxantrone at 12 mg/m(2) is a generally well-tolerated treatment that reduces disability progression and clinical exacerbations in SPMS.
• Further research is required to optimize treatment protocols and identify patient subgroups most likely to benefit.
• Long-term side effects of mitoxantrone therapy need continued investigation.